Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 4
1947 4
1948 1
1949 1
1950 4
1951 8
1952 9
1953 7
1954 8
1955 11
1956 8
1957 11
1958 8
1959 11
1960 11
1961 19
1962 13
1963 26
1964 26
1965 14
1966 13
1967 19
1968 19
1969 22
1970 24
1971 29
1972 25
1973 23
1974 20
1975 29
1976 22
1977 22
1978 18
1979 29
1980 30
1981 26
1982 16
1983 21
1984 33
1985 31
1986 24
1987 32
1988 28
1989 29
1990 26
1991 26
1992 28
1993 31
1994 46
1995 43
1996 33
1997 32
1998 48
1999 55
2000 66
2001 90
2002 109
2003 125
2004 130
2005 163
2006 157
2007 191
2008 212
2009 212
2010 228
2011 222
2012 256
2013 257
2014 259
2015 300
2016 270
2017 329
2018 354
2019 301
2020 366
2021 418
2022 419
2023 412
2024 155

Text availability

Article attribute

Article type

Publication date

Search Results

6,403 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Makarshin
Page 1
Rapid administration of undiluted intravenous levetiracetam.
Haller JT, Bonnin S, Radosevich J. Haller JT, et al. Epilepsia. 2021 Aug;62(8):1865-1870. doi: 10.1111/epi.16961. Epub 2021 Jun 24. Epilepsia. 2021. PMID: 34164804
There are limited data published demonstrating safety and tolerability of undiluted rapid intravenous (IV) push of LEV in doses of 1000 mg or less. The purpose of this study was to evaluate the safety of IV push administration of LEV doses up to 4500 mg. ...LEV …
There are limited data published demonstrating safety and tolerability of undiluted rapid intravenous (IV) push of LEV in doses of 10 …
Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review.
Steinhoff BJ, Klein P, Klitgaard H, Laloyaux C, Moseley BD, Ricchetti-Masterson K, Rosenow F, Sirven JI, Smith B, Stern JM, Toledo M, Zipfel PA, Villanueva V. Steinhoff BJ, et al. Epilepsy Behav. 2021 May;118:107939. doi: 10.1016/j.yebeh.2021.107939. Epub 2021 Apr 8. Epilepsy Behav. 2021. PMID: 33839453 Free article. Review.
While a wide range of results was reported across studies, weighted mean incidences were 5.6% for BRV, 9.9% for LEV, 12.3% for PER, and 3.1% for TPM for irritability; 3.3%* for BRV, 2.5% for LEV, 2.0% for PER, and 0.2%* for TPM for anger; and 2.5% for BRV, 2.6% for …
While a wide range of results was reported across studies, weighted mean incidences were 5.6% for BRV, 9.9% for LEV, 12.3% for PER, a …
Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for adult convulsive status epilepticus: a multicentre non-inferiority randomised control trial.
Nakamura K, Marushima A, Takahashi Y, Mochizuki M, Kimura A, Fukuda Y, Asami M, Nakamoto H, Egawa S, Kaneko J, Unemoto K, Kondo Y, Yonekawa C, Uchida M, Hoshiyama E, Yamada T, Maruo K, Ishikawa E, Matsumaru Y, Inoue Y; IENE ECT with the LIFE study group. Nakamura K, et al. J Neurol Neurosurg Psychiatry. 2023 Jan;94(1):42-48. doi: 10.1136/jnnp-2022-329485. Epub 2022 Oct 7. J Neurol Neurosurg Psychiatry. 2023. PMID: 36207063 Free PMC article. Clinical Trial.
Although fosphenytoin (FPHT) is recommended as a second-line treatment, levetiracetam (LEV) reportedly has similar efficacy, but higher safety. Therefore, we herein compared LEV with FPHT in adult SE. ...LEV may be recommended as a second-line treatment for S …
Although fosphenytoin (FPHT) is recommended as a second-line treatment, levetiracetam (LEV) reportedly has similar efficacy, but high …
The Society of Thoracic Surgeons Intermacs 2023 Annual Report: Focus on Magnetically Levitated Devices.
Jorde UP, Saeed O, Koehl D, Morris AA, Wood KL, Meyer DM, Cantor R, Jacobs JP, Kirklin JK, Pagani FD, Vega JD. Jorde UP, et al. Ann Thorac Surg. 2024 Jan;117(1):33-44. doi: 10.1016/j.athoracsur.2023.11.004. Epub 2023 Nov 8. Ann Thorac Surg. 2024. PMID: 37944655
In 2022, 2517 primary LVADs were implanted, of which 2512 (99.8%) were fully magnetically levitated (Mag-Lev) devices. This shift to nearly exclusive use of a Mag-Lev device led us to examine its outcomes compared with contemporary (2018-2022) and historical (2013-2 …
In 2022, 2517 primary LVADs were implanted, of which 2512 (99.8%) were fully magnetically levitated (Mag-Lev) devices. This shift to …
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA. Szaflarski JP, et al. Neurocrit Care. 2010 Apr;12(2):165-72. doi: 10.1007/s12028-009-9304-y. Neurocrit Care. 2010. PMID: 19898966 Clinical Trial.
METHODS: In this prospective, single-center, randomized, single-blinded comparative trial of LEV versus PHT (2:1 ratio) in patients with severe traumatic brain injury (sTBI) or subarachnoid hemorrhage (NCT00618436) patients received IV load with either LEV or fosphe …
METHODS: In this prospective, single-center, randomized, single-blinded comparative trial of LEV versus PHT (2:1 ratio) in patients w …
Levetiracetam.
Krishna K, Raut AL, Gohel KH, Dave P. Krishna K, et al. J Assoc Physicians India. 2011 Oct;59:656-8. J Assoc Physicians India. 2011. PMID: 22479748
Levetiracetam (LEV) is a novel antiepileptic drug (AED) which was discovered in early 1980s and soon, in 1999 FDA approved LEV for the management of partial onset seizure. ...Pharmacokinetics of LEV such as, less protein binding and lack of hepatic metabolism …
Levetiracetam (LEV) is a novel antiepileptic drug (AED) which was discovered in early 1980s and soon, in 1999 FDA approved LEV …
Levetiracetam-induced pancytopenia.
Alzahrani T, Kay D, Alqahtani SA, Makke Y, Lesky L, Koubeissi MZ. Alzahrani T, et al. Epilepsy Behav Case Rep. 2015 Jul 24;4:45-7. doi: 10.1016/j.ebcr.2015.06.001. eCollection 2015. Epilepsy Behav Case Rep. 2015. PMID: 26744695 Free PMC article.
Pancytopenia is a rare side effect of levetiracetam (LEV) that is associated with severe morbidity that requires hospitalization. ...The patient developed LEV-induced pancytopenia, which was successfully managed by discontinuation of this medication. ...
Pancytopenia is a rare side effect of levetiracetam (LEV) that is associated with severe morbidity that requires hospitalization. ... …
Brivaracetam efficacy and safety in focal epilepsy.
Makke Y, Abou-Khalil B. Makke Y, et al. Expert Rev Neurother. 2019 Oct;19(10):955-964. doi: 10.1080/14737175.2019.1631160. Epub 2019 Jun 24. Expert Rev Neurother. 2019. PMID: 31195850 Review.
Introduction: Brivaracetam (BRV) is an analog of levetiracetam (LEV) with 15-30 times greater affinity to SV2A and greater brain permeability than LEV. ...Behavioral adverse effects seemed less common than with LEV, and most patients switched to BRV after exp …
Introduction: Brivaracetam (BRV) is an analog of levetiracetam (LEV) with 15-30 times greater affinity to SV2A and greater brain perm …
A Systematic Review of the Efficacy of Levetiracetam in Neonatal Seizures.
McHugh DC, Lancaster S, Manganas LN. McHugh DC, et al. Neuropediatrics. 2018 Feb;49(1):12-17. doi: 10.1055/s-0037-1608653. Epub 2017 Nov 27. Neuropediatrics. 2018. PMID: 29179233 Review.
RESULTS: Five studies of LEV met all inclusion/exclusion criteria. The pooled sample size for LEV was 102 (48 received primary LEV, 54 received secondary LEV). ...Complete or near-complete seizure cessation was achieved as follows: primary LEV 3 …
RESULTS: Five studies of LEV met all inclusion/exclusion criteria. The pooled sample size for LEV was 102 (48 received primary …
Therapeutic Drug Monitoring of Levetiracetam in Select Populations.
Jarvie D, Mahmoud SH. Jarvie D, et al. J Pharm Pharm Sci. 2018;21(1s):149s-176s. doi: 10.18433/jpps30081. J Pharm Pharm Sci. 2018. PMID: 30096051 Free article. Review.
There has not been a positive correlation shown between LEV levels and efficacy or toxicity. Variable LEV levels are reported in the literature with respect to adverse effects, seizures and efficacy occurring below, within and above the supposed reference ranges. .. …
There has not been a positive correlation shown between LEV levels and efficacy or toxicity. Variable LEV levels are reported …
6,403 results